Content by ERS Genomics

|1 min read

ERS Genomics Announces Agreement with Applied StemCell to Commercialize CRISPR Gene Editing Services and Reagents

ERS Genomics holds an exclusive worldwide license from Dr. Charpentier to the foundational patents covering CRISPR/Cas9
Page 1 of 1